Delphia (USA) Inc. - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 160 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.

Quarter-by-quarter ownership
Delphia (USA) Inc. ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2022$130,528
-18.4%
10,552
-8.0%
0.15%
-17.5%
Q3 2022$160,000
-32.2%
11,466
-33.0%
0.18%
+13.0%
Q2 2022$236,000
-11.3%
17,109
+4.6%
0.16%
-18.6%
Q1 2022$266,000
+27.3%
16,353
+27.5%
0.20%
-10.4%
Q4 2021$209,00012,8300.22%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2022
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$9,514,0001.49%
CM Management, LLC 45,000$668,0000.50%
EULAV Asset Management 660,000$9,801,0000.26%
DLD Asset Management, LP 225,200$3,346,0000.24%
Virtus ETF Advisers LLC 21,387$318,0000.14%
GSA CAPITAL PARTNERS LLP 79,145$1,175,0000.12%
Hennion & Walsh Asset Management, Inc. 136,720$2,030,0000.11%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$2,507,0000.08%
Inspire Investing, LLC 31,868$473,0000.06%
DUALITY ADVISERS, LP 51,196$760,0000.06%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders